PSMA-targeted Nanoparticles for Therapy of Prostate Cancer

Description (Set) Targeted therapy for cancer has gained considerable importance recently with various improvements not only in target identification, but also in small molecule or antibody development. It has also been demonstrated that polymeric nanoparticles can passively target tumors via the enhanced permeability and retention (EPR) effect. The EPR is a property that considers that some molecules of a certain size tend to accumulate in tumors tissues more than they would accumulate in non-tumor tissues. Scientists at Johns Hopkins University have utilized a combined approach for a novel method to coat the surface of nanoparticles for therapeutic purposes as well as introduce an imaging component utilizing similar methods. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to its target and the ability of the nanoparticle to be retained for longer periods of time in the lymphatics within the tumor. Proposed Use (Set) This invention provides a novel approach for the introduction of a targeting moiety onto the surface of nanoparticles as well as a novel targeted nanoparticle that can be used for prostate cancer therapy.

Inventor(s): Denmeade, Samuel,Chandran, Sachin,Mease, Ronnie C.,Pomper, Martin Gilbert,Ray, Sangeeta

Type of Offer: Licensing



« More Medical Patents

---